e4e6 Consulting

Une excellente synthèse d’une non moins excellente table ronde (et c’est plutôt rare en fait) à laquelle j’ai eu le plaisir d’assister. Merci David Séjourné pour ce partage. #biotech #medtech #innovation ps: sans oublier un nouveau remerciement à Frédéric Girard , Olivier Chabanon et toute l’équipe de France Biotech pour l ensemble de cette soirée et de leur œuvre 😉

"Why is pet insurance easier to navigate than human health insurance?" This question, in Helen Ouyang, MD, MPH 's poignant The New York Times article sound weird to European ears. “In the end, my patient in the E.R. decided to go home that day. I reiterated how sick he was. I showed him the results that concerned me, and even tried to tell him that he could possibly die if he left the hospital. But I’m not sure how much he trusted me after my overconfident assurances that his insurance would pay; when he finally got through to an agent, he was told coverage would depend on the specifics of his care”. she says. Helen Ouyang’s heartfelt commentary on the perils of American healthcare should resonate deeply with us in Europe. Her patient’s fear of financial ruin eclipsing his medical crisis is unthinkable for many on this side of the Atlantic. Yet, her critique invites reflection: are we truly immune? While European systems (especially but not only France) are collapsing under lack of resources, operational difficulties / inefficiencies,  and administrative burdens, maintaining transparency and patient-centric care must remain non-negotiable. Dr. Ouyang’s story may feel like dystopian fiction, good material for novels or RPGs, but we must ensure they never become a European reality. The stakes are simply too high. #HealthcareSystems #PatientCareFirst #EuropeanHealthcare #PatientCentricity #LessonsFromAmerica #FutureOfHealthcare #InnovationInHealthcare

e4e6 Consulting is getting ready for its first France Biotech general assembly under the management of Olivier Chabanon et Frédéric Girard . #biotech #healthtech #medtech #innovation

🎯 Fail to Prepare, Prepare to Fail: Why Deal Success Hinges on Strategic Precision 🎯 Earlier this week, the Financial Times highlighted that the number of partnerships of biotech with big pharma has reached its lowest level in a decade. This reflects not just the growing selectivity of potential partners but also the fierce competition for deals. In such an environment, only the most well-prepared and methodically executed strategies can stand out. Experience has shown that these five principles that significantly enhance the chances of success in business development and partnerships: 1️ - Diagnosis Before Action: Start with a meticulous evaluation of assets, market potential, and gaps. Do not fool yourself, magic thought is not a pitch!! Without a clear picture of the existing landscape, it’s impossible to build a strong foundation. 2️ - Data-Driven Storytelling: A compelling narrative rooted in robust data is essential. Tailoring this story to the audience makes it both engaging and persuasive. 3️ - Iterative Refinement: Strategy documents and communication materials should evolve as insights and feedback accumulate. Staying agile ensures continued relevance. 4️ - Precision in Partner Identification: Defining criteria for partner selection, combined with openness to serendipitous opportunities, helps target the right collaborators. 5️ - Hands-On Execution: Plans must translate into action. Success hinges on effective implementation at every stage, from outreach to negotiations and follow-through. Ensure your data room is user-friendly—simplifying access for partners can significantly enhance collaboration. In today’s highly competitive landscape, integrating these principles into your approach can make the difference between missed opportunities and transformative partnerships. Looking for support in deal making? Let’s discuss how these principles can be tailored to your specific challenges and help secure your next successful deal.🚀 #HealthcareDeals #BusinessDevelopment #StrategicGrowth #Partnerships

🎯 Strategic prioritization: A cornerstone of startup success In the ever-evolving world, startups, especially in healthtech, face a myriad of strategic paths, each promising unique opportunities and challenges. The question often isn't what can be done, but what should be done first to maximize value, achieve milestones, and secure a sustainable market position. Each potential avenue, carries its own balance of risks, costs, and rewards. In order to navigate these, two conditions must be met: 1 - assessment criteria must be company specific 2 – Decision support must be a two dimension matrix balancing for example scientific potential and commercial merit. This cannot be a simple score! Mapping key factors against clear, structured criteria not only clarifies the landscape but also highlights where the greatest impact can be achieved. Such exercises are not about finding an absolute truth but about creating a robust framework for decision-making, a tool to guide action rather than paralyze it with endless possibilities. 📩 Feel free to reach out to discuss how we can help chart the best course for your business. #healthtech #startupstrategy #businessdevelopment #portfoliomanagement

Sometimes, our team is where it is not expected to be ... 😀

The nomination of Robert F. Kennedy Jr. as U.S. Secretary of Health could reshape the global biotech landscape. While aimed at making medicines more affordable, his policies could drastically impact innovation and investment in the sector, particularly for European players. In the context, it is time to act: for entrepreneurs, for investors, for governments, for Europe! If we do not want the biotech graveyard keeping on filling up, let's hear the wake up call!! Read the full article and feel free to come back with comments. #BiotechEurope #InnovationAtRisk #KennedyEffect #BiotechCrisis #PharmaUnderPressure https://lnkd.in/eHmQr78B

Les Echos ce matin font le point sur les dernières réflexions du gouvernement en matière de financement de l’innovation. Le rabotage du CIR devrait apporter 430 millions d’économies qui financeront le prolongement de du crédit d’impôt innovation et le statut de Jeune entreprise innovante (JEI) Le compromis consiste principalement + A sortir les activités liées aux brevets ou à la veille technologique du champ des dépenses éligibles au CIR ❎ Pourquoi pas? cette mesure risque d’impacter plus les grandes entreprises, qui consacrent davantage de ressources aux brevets et à la veille que les start-up. ❌ Cela pourrait-il aussi décourager la protection des innovations et, à terme, réduire l'avantage compétitif des entreprises françaises à l'international, au moins pour ce qui concerne les start up. + A supprimer le dispositif « jeunes docteurs » ❌ A l’heure où le gouvernement veut augmenter le nombre de Docteurs*, ou est la cohérence (Ah pardon, c'est le fameux "en même temps") ❌ Ce dispositif est un moyen d’inciter les entreprises à embaucher des docteurs, en valorisant leur expertise en recherche. Alors que beaucoup de jeunes docteurs "se cherchent" et où les entreprises ont besoin de leur enthousiasme et de leurs compétences, cela semble être une approche à la Gribouille + A baisser le taux applicable aux dépenses de fonctionnement de 43 % à 40 %. ❌ Cette mesure augmente le "reste à charge pour les entreprises", ce qui pourrait particulièrement affecter les startups, pour lesquelles chaque réduction de coût est vitale. En Biotech et Medtech, l'impact peut être colossal voire létal. Sérieux coups de rabot du CIR contre prolongement du CII et du statu JEI: Marché de dupe ou bon compromis? Qu'en pensez vous? * Les Echos, le 8 Novembre 2024 #CIR #Biotech #medtech #innovation #JEI https://lnkd.in/esgs7jxU

📈 As international trade enters uncharted waters, your international expansion strategy shouldn’t rely on guesswork. At e4e6 Consulting we provide SMEs and start-ups with deep expertise to help you be better prepared or strengthen your internationalization strategy. We also can help you with concrete hands-on operational support for international expansion. We give your business the resilience it needs to thrive globally—even amidst uncertainty. Want to make your international strategy stronger than political shifts? Let’s chat. #ResilientGrowth #InternationalTrade #ExportStrategy #GlobalExpansion #Healthcare #SMEs #TradeUncertainty #startups https://lnkd.in/esbuHiqS

e4e6 Consulting is a (proud) member of France Biotech and is always happy to answer questions and support Biotech, Medtech and Digital Health companies with corporate development questions from internationalisation to transaction support. Feel free to reach out. 😊 #Biotech #Medtech #DigitalHealth #esante #internationalisation